# Vico Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vico-therapeutics-b-v

- Industry: Biotechnology
- Headquarters: Netherlands
- Website: www.vicotx.com
- Total disclosed funding: $102M
- Latest round: Series B (Jun 24, 2024)
- Investors on record: 11

## About

Based in South Holland, Netherlands, and founded in 2019 and CEO Micah Mackison, Vico Therapeutics B.V. operates as a healthcare company specializing in RNA modulation on genetic neurological disorders. In June 2024, Vico Therapeutics B.V. raised EUR 11.5 million in Series B funding co-led by Seroba Life Sciences and Kurma Partners. 

Vico Therapeutics B.V. developed a product VO659, which is for treating multiple polyglutamine disorders, including spinocerebellar ataxia type 3 (SCA3), spinocerebellar ataxia type 1 (SCA1), and Huntington’s disease. The company’s product is an antisense oligonucleotide that targets the CAG repeat expansions causing these disorders. It acts in an allele-preferential manner, inhibiting the translation of the mutant mRNA transcript without altering the DNA code. The company’s platform offers various mechanisms of action, such as RNA splicing, editing, degradation, and activation, to precisely modulate RNA and correct genetic defects. 

The company plans to use the funding from June 2024 to advance their lead clinical program and further develop a portfolio of novel antisense oligonucleotides.

## Funding rounds

- Series B, Jun 24, 2024, $12M — Polaris Partners, EQT Life Sciences, Eurazeo, Seroba, Ackermans & van Haaren, Kurma Partners, Droia Ventures, Pureos Bioventures
- Series B, Jan 5, 2024, $59M — Polaris Partners, EQT Life Sciences, Eurazeo, Ackermans & van Haaren, Kurma Partners, Droia Ventures, Pureos Bioventures
- Series A, Jun 1, 2019, $30M — Idinvest Partners, Polaris Partners, EQT Life Sciences, Pontifax Venture Capital, Kurma Partners, Droia Ventures, Kinled Holding, Pureos Bioventures

## Investors

- Idinvest Partners (https://capitalatlas.ai/funds/idinvest-partners) — Series A
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A, Series B
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series A
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series A, Series B
- Droia Ventures (https://capitalatlas.ai/funds/droia-ventures) — Series A, Series B
- Kinled Holding — Series A
- Pureos Bioventures (https://capitalatlas.ai/funds/pureos-bioventures) — Series A, Series B
- Eurazeo (https://capitalatlas.ai/funds/eurazeo) — Series B
- Ackermans & van Haaren (https://capitalatlas.ai/funds/ackermans-van-haaren) — Series B
- Seroba (https://capitalatlas.ai/funds/seroba) — Series B